Mouse Monoclonal Antibodies Against Human IKKgamma/NEMO Protein

NF-kB has been found to be important in immune responses, cell proliferation, apoptosis, and in organ development. Several years ago it was discovered that an IKKgamma/NEMO protein was essential as an adaptor molecule to mediate TNF-alpha, IL-1, and oncoprotein induced activation of NF-kB. Mutation in IKKgamma/NEMO also results in two human genetic diseases, Familial incontinentia pigmenti and hypohidrotic/anhidrotic ectodermal dysplasia. The NIH announces mouse monoclonal antibodies to IKKgamma/NEMO that are far superior to other immunological reagents.

Phenylthiocarbamide (PTC) Taste Receptor

Bitter taste has evolved in mammals as a central warning signal against ingestion of poisonous or toxic compounds. However, many beneficial compounds are also bitter and taste masking of bitter tasting pharmaceutical compounds is a billion dollar industry. The diversity of compounds that elicit bitter-taste sensations is vast and more than two dozen members of the TAS2R bitter taste receptor gene family have been identified.

Construction of Recombinant Baculoviruses Carrying the Gene Encoding the Major Capsid Protein, VP1, From Calicivirus Strains (Including Norovirus Strains Toronto, Hawaii, Desert Shield, Snow Mountain, and MD145-12)

The noroviruses (known as "Norwalk-like viruses") are associated with an estimated 23,000,000 cases of acute gastroenteritis in the United States each year. Norovirus illness often occurs in outbreaks, affecting large numbers of individuals, illustrated recently by well-publicized reports of gastroenteritis outbreaks on several recreational cruise ships and in settings such as hospitals and schools. Norovirus disease is clearly important in terms of medical costs and missed workdays, and accumulating data support its emerging recognition as important agents of diarrhea-related morbidity.

Haplotypes of Human Bitter Taste Receptor Genes

Bitter taste has evolved in mammals as a crucial, important warning signal against ingestion of poisonous or toxic compounds. However, many beneficial compounds are also bitter, and taste masking of bitter tasting pharmaceutical compounds is a billion dollar industry. The diversity of compounds that elicit bitter-taste sensations is very large and more than two dozen members of the T2R bitter taste receptor family have been identified. Individuals are now known to be genetically predisposed to respond or not to respond to the bitter taste of a number of substances.

Soluble Antigen-Based ELISA for the Detection of B. malayi Infections

The technology presented is a breakthrough in the diagnosis of lymphatic filariasis, specifically targeting the B. malayi pathogen. It encompasses a novel soluble antigen extract used in both IgG and IgG4-based ELISA tests, aimed at detecting the presence of the filarial infection. This innovation serves as a cornerstone for a CLIA-certified reference test, established and utilized in Dr. Nutman's laboratory since the late 1980s.

Diagnostic Assays and Methods of Use for Detection of Filarial Infection

The effort targeting the mosquito borne neglected tropical disease lymphatic filariasis for elimination through mass drug administration by 2020 will require accurate, cost effective methods for detecting early infections. The World Health Organization-recommended immunochromatographic test detects adult Wuchereria bancrofti (Wb) antigen in blood, but shows variable efficacy due to the complex life cycle of the parasites and cross reactivity with other organisms. This variability may hinder effective lymphatic filariasis elimination efforts.

Vascularized Thyroid-on-a-Chip for Personalized Drug Screening and Disease Modeling

This technology includes a micro-engineered “thyroid-on-a-chip” that combines human thyroid organoids with integrated micro-vasculature to replicate the gland’s native blood flow and 3-D architecture, enabling rapid, patient-specific drug screening. By permitting real-time perfusion of nutrients, hormones, and immune cells, the platform yields more physiologically relevant data than conventional static cultures or animal surrogates.

Innovative Antibody Conjugates for Targeted Therapy

This advanced technology introduces innovative antibody conjugates that redefine the possibilities of targeted therapy. By coupling therapeutic agents to engineered antibodies with highly specific binding sites, these conjugates deliver treatments directly to diseased cells while sparing healthy tissues. The result is a powerful increase in treatment efficacy, accompanied by a meaningful reduction in side effects.

Subscribe to Diagnostics